{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:15:04Z","timestamp":1791342904597,"version":"4.3.1"},"reference-count":61,"publisher":"American Society of Hematology","issue":"7","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/legalcode"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Sickle cell disease (SCD) is an inherited hemolytic anemia caused by a single point mutation in the \u03b2-globin gene of hemoglobin that leads to synthesis of sickle hemoglobin (HbS) in red blood cells (RBCs). HbS polymerizes in hypoxic conditions, leading to intravascular hemolysis, release of free hemoglobin and heme, and increased adhesion of blood cells to the endothelial vasculature, which causes painful vaso-occlusion and organ damage. HbS polymerization kinetics are strongly dependent on the intracellular HbS concentration; a relatively small reduction in cellular HbS concentration may prevent HbS polymerization and its sequelae. We hypothesized that iron restriction via blocking ferroportin, the unique iron transporter in mammals, might reduce HbS concentration in RBCs, thereby decreasing hemolysis, improving blood flow, and preventing vaso-occlusive events. Indeed, vamifeport (also known as VIT-2763), a clinical-stage oral ferroportin inhibitor, reduced hemolysis markers in the Townes model of SCD. The RBC indices of vamifeport-treated male and female Townes mice exhibited changes attributable to iron-restricted erythropoiesis: decreased corpuscular hemoglobin concentration mean and mean corpuscular volume, as well as increased hypochromic and microcytic RBC fractions. Furthermore, vamifeport reduced plasma soluble VCAM-1 concentrations, which suggests lowered vascular inflammation. Accordingly, intravital video microscopy of fluorescently labeled blood cells in the microvasculature of Townes mice treated with vamifeport revealed diminished adhesion to the endothelium and improved hemodynamics. These preclinical data provide a strong proof-of-concept for vamifeport in the Townes model of SCD and support further development of this compound as a potential novel therapy in SCD.<\/jats:p>","DOI":"10.1182\/blood.2021014716","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T19:53:24Z","timestamp":1655495604000},"page":"769-781","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":30,"title":["The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease"],"prefix":"10.1182","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5986-6322","authenticated-orcid":false,"given":"Naja","family":"Nyffenegger","sequence":"first","affiliation":[{"name":"1Vifor (International) Ltd., St. Gallen, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8220-3260","authenticated-orcid":false,"given":"Rahima","family":"Zennadi","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Duke Comprehensive Sickle Cell Center, Duke University School of Medicine, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natarajaswamy","family":"Kalleda","sequence":"additional","affiliation":[{"name":"1Vifor (International) Ltd., St. Gallen, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Flace","sequence":"additional","affiliation":[{"name":"1Vifor (International) Ltd., St. Gallen, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Ingoglia","sequence":"additional","affiliation":[{"name":"1Vifor (International) Ltd., St. Gallen, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9584-3590","authenticated-orcid":false,"given":"Raphael M.","family":"Buzzi","sequence":"additional","affiliation":[{"name":"3Division of Internal Medicine, University Hospital and University of Zurich, Zurich, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Doucerain","sequence":"additional","affiliation":[{"name":"1Vifor (International) Ltd., St. Gallen, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Buehler","sequence":"additional","affiliation":[{"name":"4University of Maryland, School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik J.","family":"Schaer","sequence":"additional","affiliation":[{"name":"3Division of Internal Medicine, University Hospital and University of Zurich, Zurich, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"D\u00fcrrenberger","sequence":"additional","affiliation":[{"name":"1Vifor (International) Ltd., St. Gallen, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2072-8942","authenticated-orcid":false,"given":"Vania","family":"Manolova","sequence":"additional","affiliation":[{"name":"1Vifor (International) Ltd., St. Gallen, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2022081815223749700_B1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","article-title":"Pathophysiology of sickle cell disease","volume":"14","author":"Sundd","year":"2019","journal-title":"Annu Rev Pathol."},{"issue":"1","key":"2022081815223749700_B2","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Primers."},{"issue":"6","key":"2022081815223749700_B3","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1182\/blood.V98.6.1802","article-title":"Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase","volume":"98","author":"Wagener","year":"2001","journal-title":"Blood."},{"issue":"28","key":"2022081815223749700_B4","doi-asserted-by":"crossref","first-page":"20221","DOI":"10.1074\/jbc.M610737200","article-title":"Characterization of heme as activator of Toll-like receptor 4","volume":"282","author":"Figueiredo","year":"2007","journal-title":"J Biol Chem."},{"issue":"11","key":"2022081815223749700_B5","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1172\/JCI64578","article-title":"Extracellular hemin crisis triggers acute chest syndrome in sickle mice","volume":"123","author":"Ghosh","year":"2013","journal-title":"J Clin Invest."},{"issue":"3","key":"2022081815223749700_B6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/blood-2013-04-495887","article-title":"Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease","volume":"123","author":"Belcher","year":"2014","journal-title":"Blood."},{"issue":"2","key":"2022081815223749700_B7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/ajh.21952","article-title":"Reconstructing sickle cell disease: a data-based analysis of the \u201chyperhemolysis paradigm\u201d for pulmonary hypertension from the perspective of evidence-based medicine","volume":"86","author":"Hebbel","year":"2011","journal-title":"Am J Hematol."},{"issue":"3","key":"2022081815223749700_B8","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1172\/JCI89741","article-title":"Intravascular hemolysis and the pathophysiology of sickle cell disease","volume":"127","author":"Kato","year":"2017","journal-title":"J Clin Invest."},{"issue":"12","key":"2022081815223749700_B9","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.1073\/pnas.71.12.4864","article-title":"Kinetics and mechanism of deoxyhemoglobin S gelation: a new approach to understanding sickle cell disease","volume":"71","author":"Hofrichter","year":"1974","journal-title":"Proc Natl Acad Sci USA."},{"issue":"4","key":"2022081815223749700_B10","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1182\/blood.V47.4.621.621","article-title":"Editorial: delay time of gelation: a possible determinant of clinical severity in sickle cell disease","volume":"47","author":"Eaton","year":"1976","journal-title":"Blood."},{"issue":"5677","key":"2022081815223749700_B11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/275238a0","article-title":"Requirement for therapeutic inhibition of sickle haemoglobin gelation","volume":"275","author":"Sunshine","year":"1978","journal-title":"Nature."},{"issue":"4814","key":"2022081815223749700_B12","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1126\/science.3603036","article-title":"Delay time of hemoglobin S polymerization prevents most cells from sickling in\u00a0vivo","volume":"237","author":"Mozzarelli","year":"1987","journal-title":"Science."},{"issue":"7823","key":"2022081815223749700_B13","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0140-6736(73)93163-2","article-title":"Iron-deficiency anemia and sickle-cell disease: a hypothesis","volume":"2","author":"Lincoln","year":"1973","journal-title":"Lancet."},{"issue":"9","key":"2022081815223749700_B14","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1001\/archinte.1982.00340220035007","article-title":"Overt iron deficiency in sickle cell disease","volume":"142","author":"Haddy","year":"1982","journal-title":"Arch Intern Med."},{"issue":"9","key":"2022081815223749700_B15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1056\/NEJM198303033080918","article-title":"Improved survival of iron-deficient patients with sickle erythrocytes","volume":"308","author":"Castro","year":"1983","journal-title":"N Engl J Med."},{"issue":"2","key":"2022081815223749700_B16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/ajh.2830470203","article-title":"Improvement of sickle cell anemia by iron-limited erythropoiesis","volume":"47","author":"Castro","year":"1994","journal-title":"Am J Hematol."},{"issue":"7","key":"2022081815223749700_B17","doi-asserted-by":"crossref","first-page":"E320","DOI":"10.1002\/ajh.24380","article-title":"Iron restriction is an important treatment of hemoglobin SC disease","volume":"91","author":"Lionnet","year":"2016","journal-title":"Am J Hematol."},{"issue":"5","key":"2022081815223749700_B18","doi-asserted-by":"crossref","first-page":"541","DOI":"10.5664\/jcsm.2152","article-title":"Sickle cell anemia: iron availability and nocturnal oximetry","volume":"8","author":"Cox","year":"2012","journal-title":"J Clin Sleep Med."},{"issue":"39","key":"2022081815223749700_B19","doi-asserted-by":"crossref","first-page":"23523","DOI":"10.1074\/jbc.C115.681643","article-title":"Intestine-specific disruption of hypoxia-inducible factor (HIF)-2\u03b1 improves anemia in sickle cell disease","volume":"290","author":"Das","year":"2015","journal-title":"J Biol Chem."},{"issue":"11","key":"2022081815223749700_B20","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood.2020006919","article-title":"Dietary iron restriction improves markers of disease severity in murine sickle cell anemia","volume":"137","author":"Parrow","year":"2021","journal-title":"Blood."},{"issue":"6771","key":"2022081815223749700_B21","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/35001596","article-title":"Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter","volume":"403","author":"Donovan","year":"2000","journal-title":"Nature."},{"issue":"1","key":"2022081815223749700_B22","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI129382","article-title":"Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of \u03b2-thalassemia","volume":"130","author":"Manolova","year":"2019","journal-title":"J Clin Invest."},{"issue":"4","key":"2022081815223749700_B23","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2006-02-004812","article-title":"Correction of sickle cell disease by homologous recombination in embryonic stem cells","volume":"108","author":"Wu","year":"2006","journal-title":"Blood."},{"issue":"7","key":"2022081815223749700_B24","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood-2006-11-056101","article-title":"Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in\u00a0vivo","volume":"110","author":"Zennadi","year":"2007","journal-title":"Blood."},{"issue":"11","key":"2022081815223749700_B25","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1182\/bloodadvances.2020001642","article-title":"Mn porphyrins as a novel treatment targeting sickle cell NOXs to reverse and prevent acute vaso-occlusion in\u00a0vivo","volume":"4","author":"Thamilarasan","year":"2020","journal-title":"Blood Adv."},{"issue":"7","key":"2022081815223749700_B26","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods."},{"issue":"2","key":"2022081815223749700_B27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav Res Methods."},{"issue":"5","key":"2022081815223749700_B28","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2141.2012.09093.x","article-title":"Renal iron load in sickle cell disease is influenced by severity of haemolysis","volume":"157","author":"Vasavda","year":"2012","journal-title":"Br J Haematol."},{"issue":"22","key":"2022081815223749700_B29","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.V128.22.1276.1276","article-title":"Upregulation of renal iron metabolism in sickle cell disease mice","volume":"128","author":"Vazquez-Meves","year":"2016","journal-title":"Blood."},{"issue":"3","key":"2022081815223749700_B30","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.V98.3.860","article-title":"Characterization of the phosphatidylserine-exposing subpopulation of sickle cells","volume":"98","author":"de Jong","year":"2001","journal-title":"Blood."},{"issue":"1","key":"2022081815223749700_B31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ceca.2011.10.005","article-title":"Deoxygenation-induced and Ca(2+) dependent phosphatidylserine externalisation in red blood cells from normal individuals and sickle cell patients","volume":"51","author":"Weiss","year":"2012","journal-title":"Cell Calcium."},{"issue":"9","key":"2022081815223749700_B32","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00018-005-4527-3","article-title":"Surface exposure of phosphatidylserine in pathological cells","volume":"62","author":"Zwaal","year":"2005","journal-title":"Cell Mol Life Sci."},{"issue":"18","key":"2022081815223749700_B33","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1056\/NEJM198005013021803","article-title":"Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity","volume":"302","author":"Hebbel","year":"1980","journal-title":"N Engl J Med."},{"issue":"2","key":"2022081815223749700_B34","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2007-07-099465","article-title":"Microvascular endothelial cells express a phosphatidylserine receptor: a functionally active receptor for phosphatidylserine-positive erythrocytes","volume":"111","author":"Setty","year":"2008","journal-title":"Blood."},{"issue":"39","key":"2022081815223749700_B35","doi-asserted-by":"crossref","first-page":"E4110","DOI":"10.1073\/pnas.1405023111","article-title":"Hemolysis-induced lethality involves inflammasome activation by heme","volume":"111","author":"Dutra","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"2022081815223749700_B36","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3389\/fimmu.2020.01323","article-title":"Pro-inflammatory actions of heme and other hemoglobin-derived DAMPs","volume":"11","author":"Bozza","year":"2020","journal-title":"Front Immunol."},{"issue":"1","key":"2022081815223749700_B37","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/clin.1996.0163","article-title":"Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis","volume":"81","author":"Duits","year":"1996","journal-title":"Clin Immunol Immunopathol."},{"issue":"10","key":"2022081815223749700_B38","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1182\/blood-2002-10-3313","article-title":"Transgenic sickle mice have vascular inflammation","volume":"101","author":"Belcher","year":"2003","journal-title":"Blood."},{"issue":"26","key":"2022081815223749700_B39","doi-asserted-by":"crossref","first-page":"15215","DOI":"10.1073\/pnas.221292098","article-title":"Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease","volume":"98","author":"Aslan","year":"2001","journal-title":"Proc Natl Acad Sci USA."},{"issue":"5","key":"2022081815223749700_B40","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ajh.25443","article-title":"Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients","volume":"94","author":"Rab","year":"2019","journal-title":"Am J Hematol."},{"issue":"13","key":"2022081815223749700_B41","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood.2021012070","article-title":"Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin","volume":"138","author":"Henry","year":"2021","journal-title":"Blood."},{"issue":"2","key":"2022081815223749700_B42","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41573-018-0003-2","article-title":"Therapeutic strategies for sickle cell disease: towards a multi-agent approach","volume":"18","author":"Telen","year":"2019","journal-title":"Nat Rev Drug Discov."},{"issue":"3","key":"2022081815223749700_B43","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1172\/JCI26857","article-title":"Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice","volume":"116","author":"Belcher","year":"2006","journal-title":"J Clin Invest."},{"issue":"6","key":"2022081815223749700_B44","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1365-2141.2005.05701.x","article-title":"Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality","volume":"130","author":"Kato","year":"2005","journal-title":"Br J Haematol."},{"issue":"6","key":"2022081815223749700_B45","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood.V98.6.1955","article-title":"P-selectin mediates the adhesion of sickle erythrocytes to the endothelium","volume":"98","author":"Matsui","year":"2001","journal-title":"Blood."},{"issue":"10","key":"2022081815223749700_B46","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood-2004-02-0713","article-title":"The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in\u00a0vivo","volume":"104","author":"Embury","year":"2004","journal-title":"Blood."},{"issue":"5","key":"2022081815223749700_B47","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med."},{"issue":"1","key":"2022081815223749700_B48","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ajh.25308","article-title":"Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: a SUSTAIN study analysis","volume":"94","author":"Kutlar","year":"2019","journal-title":"Am J Hematol."},{"issue":"23","key":"2022081815223749700_B49","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. Life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"N Engl J Med."},{"key":"2022081815223749700_B50","doi-asserted-by":"crossref","first-page":"101072","DOI":"10.1016\/j.redox.2018.101072","article-title":"The impact of xanthine oxidase (XO) on hemolytic diseases","volume":"21","author":"Schmidt","year":"2019","journal-title":"Redox Biol."},{"issue":"2","key":"2022081815223749700_B51","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1161\/ATVBAHA.120.315081","article-title":"Xanthine oxidase drives hemolysis and vascular malfunction in sickle cell disease","volume":"41","author":"Schmidt","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"1","key":"2022081815223749700_B52","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajh.10313","article-title":"Iron in sickle cell disease: a review why less is better","volume":"73","author":"Koduri","year":"2003","journal-title":"Am J Hematol."},{"issue":"1","key":"2022081815223749700_B53","first-page":"e2009006","article-title":"Iron metabolism in thalassemia and sickle cell disease","volume":"1","author":"Mariani","year":"2009","journal-title":"Mediterr J Hematol Infect Dis."},{"issue":"3","key":"2022081815223749700_B54","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/jmri.21490","article-title":"Magnetic resonance detection of kidney iron deposition in sickle cell disease: a marker of chronic hemolysis","volume":"28","author":"Schein","year":"2008","journal-title":"J Magn Reson Imaging."},{"issue":"2","key":"2022081815223749700_B55","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3324\/haematol.2011.050336","article-title":"Association between hemolysis and albuminuria in adults with sickle cell anemia","volume":"97","author":"Day","year":"2012","journal-title":"Haematologica."},{"issue":"2","key":"2022081815223749700_B56","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bcmd.2010.06.003","article-title":"Alpha-thalassemia is associated with a decreased occurrence and a delayed age-at-onset of albuminuria in sickle cell anemia patients","volume":"45","author":"Nebor","year":"2010","journal-title":"Blood Cells Mol Dis."},{"issue":"1","key":"2022081815223749700_B57","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3324\/haematol.2016.154153","article-title":"APOL1, \u03b1-thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia","volume":"102","author":"Saraf","year":"2017","journal-title":"Haematologica."},{"issue":"5","key":"2022081815223749700_B58","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/ajh.23683","article-title":"Factors associated with survival in a contemporary adult sickle cell disease cohort","volume":"89","author":"Elmariah","year":"2014","journal-title":"Am J Hematol."},{"issue":"2","key":"2022081815223749700_B59","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/bcmd.2002.0489","article-title":"Amelioration of painful crises in sickle cell disease by venesections","volume":"28","author":"Rombos","year":"2002","journal-title":"Blood Cells Mol Dis."},{"issue":"14","key":"2022081815223749700_B60","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1182\/bloodadvances.2020001469","article-title":"Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events?","volume":"4","author":"Telen","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"2022081815223749700_B61","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajh.25670","article-title":"Oral ferroportin inhibitor VIT-2763: first-in-human, phase 1 study in healthy volunteers","volume":"95","author":"Richard","year":"2020","journal-title":"Am J Hematol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/7\/769\/1915118\/bloodbld2021014716.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/7\/769\/1915118\/bloodbld2021014716.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T15:26:18Z","timestamp":1660836378000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/7\/769\/485600\/The-oral-ferroportin-inhibitor-vamifeport-improves"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,8,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021014716","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]}}}